Guadecitabine - Astex Pharmaceuticals
Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; DNMT-inhibitor-SGI-110; Guadecitabine-sodium; S-110; SGI-110Latest Information Update: 05 Nov 2023
At a glance
- Originator SuperGen
- Developer Astex Pharmaceuticals; AstraZeneca; Big Ten Cancer Research Consortium; Fox Chase Cancer Center; Indiana University School of Medicine; John Hopkins University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); University of Southern California; Weill Cornell Medical College
- Class Antineoplastics; Aza compounds; Furans; Purine nucleotides; Small molecules; Triazines
- Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Phase II Fallopian tube cancer; Gastrointestinal stromal tumours; Liver cancer; Myeloproliferative disorders; Peritoneal cancer; Phaeochromocytoma; Renal cell carcinoma; Small cell lung cancer; Solid tumours; T-cell lymphoma; Urogenital cancer
- Phase I/II Bladder cancer; Colorectal cancer; Renal cancer
- Suspended Chondrosarcoma
- No development reported Cholangiocarcinoma; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Testicular cancer
- Discontinued Acute myeloid leukaemia; Ovarian cancer
Most Recent Events
- 16 May 2023 Updated efficacy data from a phase I NIBIT-M4 trial in Melanoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 31 Mar 2023 Northwestern University completes a phase-II clinical trials in Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC) (NCT02901899)
- 31 Mar 2023 Northwestern University completes a phase-II clinical trials in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC) (NCT02901899)